Pharming Group (XAMS:PHARM) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


XAMS:PHARM Pharming Group XAMS:PHARM
80 GF Score
Price €1.15
GF Value €1.26
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pharming Group Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Pharming Group's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

XAMS:PHARM vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Pharming Group's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharming Group Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Pharming Group's Margin of Safety % (DCF Earnings Based) falls into.


XAMS:PHARM
80GF Score
Pharming Group XAMS:PHARM
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pharming Group (XAMS:PHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of €1.15 is trading 8.8% below its estimated GF Value™ of €1.26. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for XAMS:PHARM:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €1.26 vs. price of €1.15 (8.8% below fair value)
  • GF Score™: 80/100 with 1 warning sign

No single metric tells the full story. See the XAMS:PHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
80GF Score

Get the complete analysis for XAMS:PHARM

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.15
Price
€1.26
GF Value